Alnylam Pharmaceuticals, Inc.
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Last updated:
Abstract:
The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.
Status:
Grant
Type:
Utility
Filling date:
1 May 2020
Issue date:
29 Mar 2022